Patents by Inventor Marion T. Kasaian
Marion T. Kasaian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8221752Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: GrantFiled: October 8, 2009Date of Patent: July 17, 2012Assignee: Wyeth LLCInventors: Marion T. Kasaian, Lioudmila Gennadievna Tchistiakova, Geertruida Machteld Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Publication number: 20110262435Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: ApplicationFiled: May 2, 2011Publication date: October 27, 2011Applicant: Wyeth LLCInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Patent number: 7943342Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: GrantFiled: January 22, 2009Date of Patent: May 17, 2011Assignee: Wyeth LLCInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20100129360Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: ApplicationFiled: October 8, 2009Publication date: May 27, 2010Applicant: WYETH LLCInventors: Marion T. Kasaian, Lioudmila Gennadievna Tchistiakova, Geertruida Machteld Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Patent number: 7615213Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: GrantFiled: June 9, 2005Date of Patent: November 10, 2009Assignee: WyethInventors: Marion T. Kasaian, Lioudmila Tchistiakova, Geertruida M. Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Publication number: 20090274705Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: ApplicationFiled: January 22, 2009Publication date: November 5, 2009Applicant: WYETHInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20090098142Abstract: Methods and compositions for treating and/or monitoring treatment of IL-13-associated disorders or conditions are disclosed.Type: ApplicationFiled: December 11, 2007Publication date: April 16, 2009Inventors: Marion T. Kasaian, Timothy A. Cook, Samuel J. Goldman, Donald G. Raible
-
Patent number: 7501121Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.Type: GrantFiled: June 17, 2005Date of Patent: March 10, 2009Assignee: WyethInventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
-
Publication number: 20080241098Abstract: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).Type: ApplicationFiled: November 29, 2007Publication date: October 2, 2008Applicant: WYETHInventors: Deborah A. Young, Mary Collins, Kyriaki Dunussi-Joannopoulos, Richard Michael O'Hara, Marion T. Kasaian, Matthew J. Whitters
-
Patent number: 7198789Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.Type: GrantFiled: October 4, 2002Date of Patent: April 3, 2007Assignee: Genetics Institute, LLCInventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
-
Publication number: 20030108549Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.Type: ApplicationFiled: October 4, 2002Publication date: June 12, 2003Applicant: WyethInventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger